| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |